Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Algeta brings in NOK245mm through private placement

Executive Summary

Cancer therapeutics developer Algeta ASA raised NOK245mm ($35.7mm) through the private placement of 22.3mm shares at NOK11 each (a 32% discount) to a group of new and existing investors led by Abingworth. The company could bring in an additional NOK35mm through a second closing. Funds will be put towards Phase III trials of Algeta's lead candidate Alpharadin, an alpha-emitting compound based on radium-223 for bone metastases of prostate cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies